New drug combo shows promise against tough lymphoma
NCT ID NCT04067037
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy (AVD) can improve outcomes for people with advanced classical Hodgkin lymphoma who have not yet been treated. About 60 adults aged 18 to 75 will receive the combination for up to six cycles. The main goal is to see how many achieve a complete metabolic response, meaning no signs of active cancer on scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab (an immunotherapy drug) combined with chemotherapy (epirubicin, vincristine, dacarbazine)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for advanced Hodgkin lymphoma, potentially improving response rates without long-term medication.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 60 participants and no comparison group. Results may not confirm benefit, and side effects from immunotherapy plus chemotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
An Yang Tumor Hospital
Anyang, Henan, 455000, China
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
-
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial